Shandong Boan Biotechnology Co (FRA:UJ9) Piotroski F-Score: 5 (As of Jun. 30, 2026) — Near Median


FRA:UJ9 Shandong Boan Biotechnology Co Ltd FRA:UJ9
44 GF Score
Price €0.51
GF Value €1.69
! 5 Warning Signs
View Full Analysis

What is Shandong Boan Biotechnology Co Piotroski F-Score?

Shandong Boan Biotechnology Co FRA:UJ9 +1.00% 44 Piotroski F-Score is 5 as of Jun. 30, 2026, which is at its 10-year median of 5.00. GuruFocus rates FRA:UJ9 with a GF Score™ of 44/100 and a GF Value™ of €1.69. The stock has 5 warning signs investors should review. Among 1,339 Biotechnology companies, Shandong Boan Biotechnology Co ranks better than 85.06% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Shandong Boan Biotechnology Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Shandong Boan Biotechnology Co's Piotroski F-Score or its related term are showing as below:

FRA:UJ9' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 6
Current: 5

During the past 6 years, the highest Piotroski F-Score of Shandong Boan Biotechnology Co was 6. The lowest was 3. And the median was 5.

Shandong Boan Biotechnology Co  (FRA:UJ9) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Shandong Boan Biotechnology Co Piotroski F-Score Related Terms


Shandong Boan Biotechnology Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Shandong Boan Biotechnology Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shandong Boan Biotechnology Co Piotroski F-Score Chart

Shandong Boan Biotechnology Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial N/A 6.00 3.00 5.00 5.00

Shandong Boan Biotechnology Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 3.00 0.00 5.00 0.00 5.00

FRA:UJ9 vs VRTX, REGN, ALNY: Piotroski F-Score Comparison

For the Biotechnology subindustry, Shandong Boan Biotechnology Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shandong Boan Biotechnology Co Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shandong Boan Biotechnology Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Shandong Boan Biotechnology Co's Piotroski F-Score falls into.


FRA:UJ9
44GF Score
Shandong Boan Biotechnology Co Ltd FRA:UJ9
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was €0.87 Mil.
Cash Flow from Operations was €7.87 Mil.
Revenue was €95.16 Mil.
Gross Profit was €68.20 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was (374 + 500.241) / 2 = €437.1205 Mil.
Total Assets at the begining of this year (Dec24) was €374.00 Mil.
Long-Term Debt & Capital Lease Obligation was €38.03 Mil.
Total Current Assets was €244.12 Mil.
Total Current Liabilities was €104.84 Mil.
Net Income was €9.60 Mil.

Revenue was €95.27 Mil.
Gross Profit was €71.18 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was (298.387 + 374) / 2 = €336.1935 Mil.
Total Assets at the begining of last year (Dec23) was €298.39 Mil.
Long-Term Debt & Capital Lease Obligation was €56.36 Mil.
Total Current Assets was €125.43 Mil.
Total Current Liabilities was €85.09 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Shandong Boan Biotechnology Co's current Net Income (TTM) was 0.87. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Shandong Boan Biotechnology Co's current Cash Flow from Operations (TTM) was 7.87. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=0.866/374
=0.00231551

ROA (Last Year)=Net Income/Total Assets (Dec23)
=9.6/298.387
=0.03217298

Shandong Boan Biotechnology Co's return on assets of this year was 0.00231551. Shandong Boan Biotechnology Co's return on assets of last year was 0.03217298. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Shandong Boan Biotechnology Co's current Net Income (TTM) was 0.87. Shandong Boan Biotechnology Co's current Cash Flow from Operations (TTM) was 7.87. ==> 7.87 > 0.87 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=38.029/437.1205
=0.08699889

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=56.364/336.1935
=0.16765345

Shandong Boan Biotechnology Co's gearing of this year was 0.08699889. Shandong Boan Biotechnology Co's gearing of last year was 0.16765345. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=244.117/104.84
=2.32847196

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=125.434/85.087
=1.47418525

Shandong Boan Biotechnology Co's current ratio of this year was 2.32847196. Shandong Boan Biotechnology Co's current ratio of last year was 1.47418525. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Shandong Boan Biotechnology Co's number of shares in issue this year was 575.57. Shandong Boan Biotechnology Co's number of shares in issue last year was 535.934. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=68.196/95.161
=0.71663812

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=71.179/95.27
=0.74712921

Shandong Boan Biotechnology Co's gross margin of this year was 0.71663812. Shandong Boan Biotechnology Co's gross margin of last year was 0.74712921. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=95.161/374
=0.25444118

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=95.27/298.387
=0.31928335

Shandong Boan Biotechnology Co's asset turnover of this year was 0.25444118. Shandong Boan Biotechnology Co's asset turnover of last year was 0.31928335. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+1+0+0+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Shandong Boan Biotechnology Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
Shandong Boan Biotechnology Co (FRA:UJ9) has a Piotroski F-Score of 5 as of Jun. 30, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Shandong Boan Biotechnology Co and its competitors. This is near median its historical median of 5.00. Over the past decade, Shandong Boan Biotechnology Co's Piotroski F-Score has ranged from 3.00 to 6.00. According to the industry distribution chart, Shandong Boan Biotechnology Co ranks #200 out of 1339 companies in the Biotechnology industry, placing it in the top 14.9%.
Is Shandong Boan Biotechnology Co's Piotroski F-Score too high?
Shandong Boan Biotechnology Co's current Piotroski F-Score of 5 is near median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 6.00. The Biotechnology industry median Piotroski F-Score is 3.00. Shandong Boan Biotechnology Co's value of 5 is 66.7% above this industry median. Based on the distribution chart, Shandong Boan Biotechnology Co ranks #200 out of 1339 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Shandong Boan Biotechnology Co has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Shandong Boan Biotechnology Co's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shandong Boan Biotechnology Co ranks #200 out of 1339 companies for Piotroski F-Score. This places Shandong Boan Biotechnology Co in the top 15% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 3.00. Shandong Boan Biotechnology Co's value of 5 is 66.7% above this benchmark. Historically, Shandong Boan Biotechnology Co's own Piotroski F-Score has ranged from 3.00 to 6.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 3.00, Shandong Boan Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,339 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shandong Boan Biotechnology Co's current Piotroski F-Score of 5 is 66.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Shandong Boan Biotechnology Co and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shandong Boan Biotechnology Co's current Piotroski F-Score is 5, which is near median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Boan Biotechnology Co stock overvalued right now?
Shandong Boan Biotechnology Co (FRA:UJ9) has a current Piotroski F-Score of 5. The stock's GF Value™ is €1.69, compared to a current price of €0.51 — trading 70.1% below its estimated fair value. The current Piotroski F-Score is 5, which is near median its 10-year median of 5.00 and 66.7% above the Biotechnology industry median of 3.00. Shandong Boan Biotechnology Co's overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Shandong Boan Biotechnology Co (FRA:UJ9), the current Piotroski F-Score is 5 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shandong Boan Biotechnology Co (FRA:UJ9) Overvalued in 2026?

Based on GuruFocus' analysis, Shandong Boan Biotechnology Co stock appears to be undervalued. The current stock price of €0.51 is trading 70.1% below its estimated GF Value™ of €1.69.

Key valuation signals for FRA:UJ9:

  • Piotroski F-Score: 5 (near median its 10-year median of 5.00)
  • GF Value™: €1.69 vs. price of €0.51 (70.1% below fair value)
  • GF Score™: 44/100 with 5 warning signs
  • Industry Position: 66.7% above the Biotechnology median (#200 of 1339)

No single metric tells the full story. See the FRA:UJ9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shandong Boan Biotechnology Co Business Description

Other Exchanges 06955:Hong Kong
Address No. 39 Keji Avenue, High-Tech Industrial Development Zone, Shandong Province, Yantai, CHN
Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. It is focused on developing, manufacturing, and marketing biologics, with a focus on oncology, autoimmune diseases, ophthalmology, and metabolic diseases. The company's drug discovery activities revolve around multiple platforms: Fully Human Antibody Platform, bsAb/msAb/Probody Platform, and ADC Platform. It has commercialized several products, such as Boyounuo, Boyoubei (denosumab injection 60 mg), Boluojia (denosumab injection 120 mg), Boyouping (dulaglutide injection), and Boyoujing; and is actively engaged in the development of other drugs like BA1104 (nivolumab injection), BA1106, BA1302 (an anti-CD228 ADC), etc. Geographically, the company generates maximum revenue from the Chinese mainland.
44GF Score

Get the complete analysis for FRA:UJ9

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.51
Price
€1.69
GF Value